217 related articles for article (PubMed ID: 29849845)
1. Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects.
Webster LR; Pantaleon C; Iverson M; Smith MD; Kinzler ER; Aigner S
Pain Res Manag; 2018; 2018():7276021. PubMed ID: 29849845
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER.
Webster LR; Pantaleon C; Shah MS; DiFalco R; Iverson M; Smith MD; Kinzler ER; Aigner S
Pain Med; 2017 Jul; 18(7):1303-1313. PubMed ID: 27651506
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
4. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.
Webster LR; Smith MD; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 Sep; 18(9):1695-1705. PubMed ID: 27651510
[TBL] [Abstract][Full Text] [Related]
5. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
Kinzler ER; Pantaleon C; Aigner S
Clin Ther; 2018 Aug; 40(8):1357-1365. PubMed ID: 30049503
[TBL] [Abstract][Full Text] [Related]
6. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
[TBL] [Abstract][Full Text] [Related]
7. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
Setnik B; Sommerville K; Goli V; Han L; Webster L
Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
Webster LR; Iverson M; Pantaleon C; Smith MD; Kinzler ER; Aigner S
Pain Med; 2019 Apr; 20(4):747-757. PubMed ID: 29608768
[TBL] [Abstract][Full Text] [Related]
9. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.
Smith MD; Webster LR; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 May; 18(5):898-907. PubMed ID: 27633773
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Bond M; Schoedel KA; Rabinovich-Guilatt L; Gasior M; Tracewell W; Malamut R; Ma Y; Webster LR
Pain Med; 2018 Aug; 19(8):1597-1612. PubMed ID: 29016880
[TBL] [Abstract][Full Text] [Related]
11. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
[TBL] [Abstract][Full Text] [Related]
12. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
[TBL] [Abstract][Full Text] [Related]
13. Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.
Harris SC; Cipriano A; Colucci SV; Kapil RP; Geoffroy P; Hopyan T; Levy-Cooperman N
Pain Med; 2016 May; 17(5):820-31. PubMed ID: 26814240
[TBL] [Abstract][Full Text] [Related]
14. Syringeability of morphine ARER, a novel, abuse-deterrent, extended-release morphine formulation.
Kinzler ER; Pantaleon C; Iverson MS; Aigner S
Am J Drug Alcohol Abuse; 2019; 45(4):377-384. PubMed ID: 30990363
[No Abstract] [Full Text] [Related]
15. A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.
Webster LR; Kopecky EA; Smith MD; Fleming AB
Pain Med; 2016 Jun; 17(6):1112-30. PubMed ID: 26814256
[TBL] [Abstract][Full Text] [Related]
16. Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Darwish M; Bond M; Ma Y; Tracewell W; Robertson P; Webster LR
Pain Med; 2017 Jan; 18(1):61-77. PubMed ID: 27330154
[TBL] [Abstract][Full Text] [Related]
17. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
Harris SC; Perrino PJ; Smith I; Shram MJ; Colucci SV; Bartlett C; Sellers EM
J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
Meske D; Kopecky EA; Passik S; Shram MJ
J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and Pharmacodynamic Correlations From 2 Studies Evaluating Abuse Potential of Hydrocodone Extended-Release Tablets.
Schoedel KA; Gillespie M; Levy-Cooperman N; Shram MJ; Rabinovich-Guilatt L
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):32-39. PubMed ID: 29723441
[TBL] [Abstract][Full Text] [Related]
20. Oral Human Abuse Potential of Oxycodone DETERx
Kopecky EA; Fleming AB; Levy-Cooperman N; O'Connor M; M Sellers E
J Clin Pharmacol; 2017 Apr; 57(4):500-512. PubMed ID: 27669664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
